The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
Dr. Reddy's Laboratories has been issued a Form 483 with four observations
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
The collaboration between CORONA and Ferring will cater to patients across India
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
Subscribe To Our Newsletter & Stay Updated
